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Abstract  
Objectives: To evaluate the detection rates of targeted and systematic biopsies in 
magnetic resonance (MRI) and transrectal ultrasound (US) image-fusion 
transperineal prostate biopsy for patients with previous benign transrectal US 
guided biopsies in two high-volume centres. 
Patients and methods: Two centre, prospective outcome study of 487 patients with 
previous benign biopsies that underwent transperineal MRI/US fusion-guided target 
and systematic saturation biopsy from 2012 to 2015. MRI was reported according to 
PIRADS Version 1. Detection of Gleason score (GS) 7-10 cancer (PCa) on biopsy was 
the primary outcome. Positive (PPV) and negative (NPV) predictive values including 
95% confidence intervals were calculated. Detection rates of targeted and 
systematic biopsies were compared using McNemar’s test. 
Results: Median PSA was 9.0 (IQR 6.7-13.4) ng/ml. PIRADS 3-5 MRI lesions were 
reported in 343 (70%) patients. GS 7-10 PCa was detected in 149 (31%). PPV for 
detecting GS 7-10 PCa was 0.20 (±0.07) for PIRADS 3, 0.32 (±0.09) for PIRADS 4, and 
0.70 (±0.08) for PIRADS 5. NPV of PIRADS 1-2 was 0.92 (±0.04) for GS 7-10 and 0.99 
(±0.02) for GS ≥ 4+3 cancer. Systematic biopsies alone found 125/138 (91%) GS 7-10 
cancers. In patients with suspicious lesions (PIRADS 4-5) on MRI, systematic biopsies 
would not have detected 12/113 significant PCa (11%), while targeted biopsies alone 
would have failed to diagnose 10/113 (9%). In equivocal lesions (PIRADS 3), targeted 
biopsy alone would not have diagnosed 14/25 (56%) of GS 7-10, whereas systematic 
biopsies alone would have missed 1/25 (4%). Combination with PSA-density 
improved the AUC of PIRADS from 0.822 to 0.846. 
Conclusion:  
In patients with high probability MRI lesions, the highest detection rates of GS 7-10 
cancer still required combined targeted and systematic MRI/TRUS image-fusion, 
however, systematic biopsy alone may be sufficient in patients with equivocal 
lesions. Repeated prostate biopsies may not be needed at all for patients with a low 
PSA-density and a negative MRI read by experienced radiologists. 
 
 
Introduction 
Multiparametric magnetic resonance imaging (MRI) of the prostate plays an 
increasingly important role in prostate cancer (PCa) diagnostics. A non-suspicious 
MRI has a high negative predictive value (NPV) for the detection of Gleason score 
(GS) ≥7 cancer on biopsy [1-4] International guidelines therefore currently 
recommend MRI of the prostate for men with previous negative biopsies and for 
staging purposes in patients with biopsy proven cancer [5-7]. The use of MRI/TRUS 
image-fusion promises to be useful in primary biopsy.  Most importantly, the 
technique may provide more accurate primary risk stratification [8-10]: Localisation, 
extent and GS of cancer found in fusion biopsies correlate with the final result of 
prostatectomy specimens [11,12]. Yet, MRI may miss GS ≥7 cancer in 8-24% of 
patients, when a radical prostatectomy specimen is used as the reference method 
[13-15]. There is conflicting evidence whether targeted biopsies alone or a 
combination of targeted and systematic biopsies are the best approach as well as 
controversy to the number of cores taken and the route [16] [10,15,17-20]. Given 
the conflicting evidence to date, the aim of our study was therefore to prospectively 
clarify the detection rates of targeted and systematic transperineal MR/US image-
fusion prostate biopsies in patients with previous negative transrectal US guided 
biopsies using the data from two different tertiary referral centres. 
Patients and Methods 
Standards of reporting  
The Standards of Reporting for MRI-targeted Biopsy Studies (START) were used to 
describe the study population, the conduct and reporting of the MRI, the conduct of 
the biopsy, and the results [21]. The biopsy technique and data collection was 
prospectively standardised according to the Ginsburg consensus [22]. 
 
Study population 
Patients with previous negative TRUS biopsies according to local standard without 
the diagnosis or treatment of prostate cancer were included in the evaluation. From 
10/2012 to 11/2015, 287 patients underwent multiparametric MRI and subsequent 
transperineal prostate biopsies in centre 1, and 200 patients in centre 2. None of the 
patients had previously undergone transperineal biopsy. The objective was to 
identify clinically significant cancer, defined as Gleason score 7-10. The final study 
cohort comprised 487 patients. The indication for repeat biopsy in the patients were 
either rising PSA values (n=404) or a previous biopsy specimen showing suspicion of 
cancer (atypical small acinar proliferation) or multifocal high-grade prostatic 
intraepithelial neoplasia (n=83). The patients’ clinical characteristics are shown in 
Table 1.  
 
Ethical approval  
All patients were counselled about the risks of the procedure and thereafter signed a 
consent form that included a permission to use their clinical data for research. The 
study was approved as a service evaluation by local ethics and audit committees in 
both centres. 
 
Magnetic resonance imaging 
In centre 1, all patients underwent prostate MRI on a 3.0 T Magnetom (Siemens, 
Erlangen, Germany) with the use of the manufacturer´s standard multi-channel body 
coil and integrated spin phased-array coil as previously described [15]. Patients in 
centre 2 underwent prostate MRI on a 1.5 T MR450 (n=20) or 3.0 T Discovery MR750 
HDx (n=180) (GE Healthcare, Waukesha, USA) with an 8-16 channel surface phased 
array coil as previously described [4] The MR imaging protocols are shown in 
Supplementary Table 1. 
 
Image analysis 
The MRIs were read by at least one uro-radiologists with more than 3 years’ 
experience of prostate MRI at a high-volume prostate cancer centre. All radiologists 
have ongoing histological feedback on more than 150 MRI per year. Images were 
analysed according to the Prostate Imaging-Reporting and Data System (PIRADS) 
version 1 [23] and a final score was defined by combining all three scores for T2w, 
DWI and DCE, respectively according to criteria as described in PIRADS version 2 
[24].  
 
Biopsy 
The BiopseeTM MRI/TRUS fusion biopsy system (Medcom, Darmstadt, Germany) was 
used for all biopsies. All men underwent systematic transperineal biopsies volume-
based with a median of 24 cores according to the Ginsburg protocol [4,22]. In 
patients with PIRADS 3-5 MRI lesions, at least 2 biopsy cores were taken from each 
lesion before the systematic biopsies. All procedures were done by residents in 
Urology in centre 1 and by 1 of 3 urologists with several years’ experience of 
transperineal biopsy in centre 2. 
 
Histopathology 
For the time period of this study, all biopsies were graded with a Gleason score 
according to the ISUP 2005 recommendations by at least one specialist 
uropathologist [25]. The final histology result following this specialist assessment 
was used as data for this study. According to the recently internationally accepted 
new prostate cancer grading system, adopted by the WHO in 2016, the clinically 
significant cancers as defined in this study as Gleason Score 7-10 would be 
equivalent to combined Grade Groups 2-5, with Gleason score 4+3=7 alone being 
Grade Group 3,  and those Gleason Score 6 cancers regarded as clinically insignificant 
are equivalent to Grade Group 1 [26]. 
 
Statistics 
All data was collected prospectively in each centre. Descriptive statistics were used 
and positive (PPV) and negative (NPV) predictive values including 95% confidence 
intervals were calculated, using the combined systematic transperineal biopsy +/- 
targeted biopsies as reference test, which has been recently validated [15]. In 
addition, predictive values and detection rates were calculated for PSA-densities of ≤ 
0.15 ng/ml/cm3 and > 0.15 ng/ml/cm3. Detection rates of targeted and systematic 
cores were compared for each centre and combined. McNemar test was used to test 
for statistical significance. Statistics was done using IBM SPSS Statistics 22 (IBM, 
Armonk, USA). 
 
 
  
Results 
The distribution of MRI findings is shown is Table 2. One or more lesion suspicious 
for cancer on MRI (PIRADS 3-5) was found in 70% of the patients. The median 
number of target lesions was 1 (IQR: 1-3). The median number of targeted biopsy 
cores per patient was 3 (IQR: 2-4) and the median number of systematic cores was 
24 (IQR 24-26).  
 
Prostate cancer detection, NPV and PPV of MRI 
The biopsy results are shown in Table 3. Gleason score 7-10 cancer was detected in 
31% (149/487) of the patients. In our study, 13/87 GS 7-10 cancers in centre 1 and 
27/62 in centre 2 were found exclusively in the anterior zone of the prostate, 
resulting in 27% of clinically significant tumours. Nevertheless, the other 73% were 
found in areas supposedly representatively sampled previously by TRUS biopsies.  
The systematic biopsies in the 144 patients with PIRADS 1-2 MRI findings (i.e. with 
no suspicious lesion) detected cancer in 40 patients (28%), the majority of whom had 
Gleason score 6 cancer (29 patients). The NPV of PIRADS 1-2 findings was 0.72 for 
excluding any cancer, 0.92 for excluding Gleason score 7-10 and 0.99 for excluding 
Gleason score ≥ 4+3=7 cancer (Table 4), with no significant differences between the 
centres. Of 11 (8%) GS 7-10 cancers in 144 patients with PIRADS 1-2 lesions were 10 
(7%) GS 3+4 and 1 (1%) GS 8.   
 
PIRADS 3-5 lesions were found on MRI in 343 men. The targeted and systematic 
biopsies detected cancer in 209 (61%) and GS 7-10 cancer in 138 (40%) of these 
patients. The PPV of MRI PIRADS 3-5 was 0.61 for detecting any cancer, 0.40 for 
detecting GS 7-10 cancer, and 0.20 for detecting GS ≥ 4+3=7 cancer. The PPV 
increased with increasing PIRADS score: the PPV for detecting 7-10 cancer was 0.20 
for PIRADS 3, 0.32 for PIRADS 4, and 0.70 for PIRADS 5, with no significant difference 
between both centres. The PPVs for any and for GS ≥ 3+4=7 cancer, stratified for the 
3 different patient groups, are shown in Table 4. Of 25 (20%) GS 7-10 cancers in 128 
patients with an equivocal PIRADS 3 lesion on MRI, 13 (10%) were GS 3+4, 9 (7%) GS 
4+3, and 3 (2%) GS 8-10.  
 
Combination of PIRADS and PSA-density 
Taking PSA-density into account improved the predictive values of PIRADS 3-5. The 
NPV of PIRADS 1-2 findings for excluding GS 7-10 cancer was 0.93 (79/85) for men 
with a PSA-density ≤ 0.15 ng/ml/cm3 and 0.92 (54/59) for men with a PSA-density > 
0.15 ng/ml/cm3. Positive predictive values were higher with rising PSA-density, from 
0.11 with a PSA-Density ≤ 0.15 ng/ml/cm3 to 0.33 with a PSA-Density > 0.15 
ng/ml/cm3 for PIRADS 3 lesions and from 0.33 with ≤ 0.15 ng/ml/cm3 to 0.65 with > 
0.15 ng/ml/cm3 for PIRADS 4-5 lesions (Table 5). The area under the curve (AUC) for 
the two density-groups alone was 0.674 and for PIRADS alone 0.822. The 
combination of both improved the AUC to 0.846, which is significant compared to 
PIRADS alone (p=0.046) (Figure 2). 
 
Comparison of detection rates in targeted and systematic cores 
Systematic biopsies in patients with PIRADS 3-5 lesions on MRI did not detect 13/138 
significant PCa with 2 GS 3+4, 11 GS 4+3. Targeted biopsies of PIRADS 3-5 lesions 
alone failed to diagnose 24/138 significant PCa with 8 GS 3+4, 12 GS 4+3 and 4 GS 8-
10. A combination of targeted and systematic biopsies was significantly better than 
either method alone for the detection of significant GS 7-10 cancer (p=0.0001-
0.0009) (Table 6). Systematic biopsies alone in patients with suspicious lesions 
(PIRADS 4-5) on MRI would not have detected 12/113 significant PCa  (p=0.0015) 
while performing only targeted biopsies of suspicious lesions would have failed to 
diagnose 10/113 significant PCa (p=0.0044). In equivocal lesions (PIRADS 3), targeted 
biopsy alone would not have diagnosed 14/25 of GS 7-10, whereas performing only 
systematic biopsies would have only missed 1/25 GS 4+3 cancer, with no significant 
difference in detection rate between systematic and combined biopsy (p=1.0).  
Discussion 
Our report presents the largest series of MRI/TRUS image-fusion guided 
transperineal prostate biopsies in patients with previous negative TRUS biopsies, 
with the advantage of a multicentre comparison based on a prospectively 
standardised technique and data collection to evaluate the introduction of the use of 
MRI-based diagnostics in our centres.  
 
Despite previous negative conventional transrectal biopsies, 51% of patients had 
cancer in the transperineal MR/US fusion biopsy and 31% had clinically significant 
disease. 73% GS 7-10 cancers were found in the previously sampled mid to posterior 
zone of the prostate. With a suspicious MRI (PIRADS 4-5), detection rates rose to 
71% for any cancer and 53% with GS 7-10. With a non-suspicious MRI (PIRADS 1-2), 
the negative predictive value for excluding Gleason score 7-10 cancer was 92%, using 
systematic transperineal saturation biopsy as reference test. Our results suggest that 
in men without suspicious lesions on high quality MR imaging, biopsy might be 
omitted altogether, and replicate the high negative predictive values that have been 
repeatedly published previously [4,17,19,27,28]. In our study, 11 (8%) GS 7-10 
cancers in 144 patients with PIRADS 1-2 MRI would have remained undiagnosed, 
only 1/11 being a GS ≥ 4+3, whilst sparing 144 men (30%) a repeat biopsy. By adding 
a PSA density cutoff, it may be possible to further increase the negative predictive 
value of mpMRI [29]. In our study, the NPV of MRI for men with PSA-density <0.15 
was 0.93, with 5 GS 3+4 and 1 GS 8. 
 
The combination of targeted and systematic biopsies was significantly superior to 
either method alone for the detection of significant GS 7-10 cancer (p=0.0001-
0.0009). This multicentre result complements previous results from Radtke et al. in 
prostatectomy patients [15]. Several other studies have compared MR/US targeted 
biopsy to systematic ultrasound-guided (TRUS) biopsy with diverging results 
depending on type of systematic biopsy employed or number of cores taken: Some 
found that MR/US fusion targeted transrectal biopsy leads to increased detection of 
high-risk cancer and decreased detection of low-risk cancer but missed up to 6% 
higher risk tumors [10,17,30,31], others found similar detection rates in systematic 
and targeted transrectal biopsies [18,32].  
 
In patients with equivocal lesions (PIRADS 3), there was no significant difference 
between systematic biopsies alone and the combination of both targeted and 
systematic biopsy methods (p=1.000). Systematic biopsies alone would have missed 
only 1/25 (4%) GS 7-10 cancer, whereas targeted biopsy alone would not have 
diagnosed 14/25 (56%) of GS 7-10. These results suggest that the confidence of our 
radiologist to call the visible lesion significant (PIRADS 4 instead of 3) was clearly and 
rightly low which is proven by the fact that the addition of targeted biopsy does not 
add value to systematic biopsies in this group. Work is needed to distinguish these 
equivocal lesions further into insignificant and significant. When counselling such 
patients whether or not and how to undergo repeat biopsy, urologists should include 
clinical risk factors like PSA, and PSA density. In our study, equivocal (PIRADS 3) 
lesions on MRI in patients with a low PSA density had a NPV of 0.89. Proceeding 
without biopsy can be considered for such patients with follow-up in place. 
 
For suspicious lesions (PIRADS 4-5), both biopsy methods alone were inferior to the 
combination of both (p =0.0001 and p=0.0009) but systematic biopsies missed more 
significant PCA (12/113) than targeted biopsy (10/113). These results stress the need 
to improve the technique of targeted biopsies before an omission of systematic 
biopsies in patients with suspicious MRI can be taken into further consideration. 
Failure to detect significant cancer in targeted biopsies can have several 
explanations: communication of reports between radiology and urology, patient 
factors, fusion-technique, and biopsy core number can affect the accuracy of cancer 
detection. Additionally, patient positioning, breathing movements, and deformation 
of the prostate gland during the biopsy procedure can lead to incorrect fusion of 
previously acquired MR images and real-time ultrasound despite using software 
registration, general anaesthesia and experienced operators. A way to overcome 
these limitations, would be the use of “saturation” target cores, with more cores per 
lesion to improve detection rates. For this reason, centre 1 had started to take a 
minimum of 4 targeted biopsies per lesion or more (Figure 1) towards the end of the 
study period and centre 2 since analysis of joint data was available.  
 
A strength of our study is that we prospectively collected data on a repeat biopsy 
population in a multicentre setting using a combination of targeted and systematic 
transperineal saturation biopsy as the reference. Next to radical prostatectomy 
specimens and transperineal mapping, this is the most valid means of assessing for 
clinically significant PCa, especially in a patient population in which not all patients 
need to undergo prostatectomy.  
 
Our study has several limitations. Despite prospective collection of data, the analysis 
performed was retrospectively. Our results cannot necessarily be applied to patients 
without previous biopsies. As Radtke et al. and Hansen et al demonstrated, first 
biopsy patients are more likely to have higher predictive values in transperineal 
MR/US fusion biopsy than patients with previous negative TRUS biopsies [4,19]. Also, 
the high cancer detection rate in systematic cores could be influenced by the fact 
that these also included the cores from the sector where a target was found, 
resulting in a possible bias to resampling the targets as urologists were not blinded 
to them. We also acknowledge that the parameter of GS 7-10 cancer as the 
definition of clinically significant cancer is debatable. Our analysis has not taken into 
account the amount of large volume GS 6 or small volume GS 3+4. The incorporation 
of cancer volume via the number of infiltrated cores and the maximum cancer core 
length is currently being incorporated into clinical practice.  
 
 
 
Conclusion 
In patients with high probability MRI lesions, the highest detection rates of GS 7-10 
cancer still required combined targeted and systematic MRI/TRUS image-fusion, 
however, systematic biopsy alone may be sufficient in patients with equivocal 
lesions. Repeated prostate biopsies may not be needed at all for patients with a low 
PSA-density and a negative MRI read by experienced radiologists. 
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Figures 
Figure 1.  Patient with two suspicious MRI lesions with four targeted cores in each 
lesion (L26-L29 in lesion 1; L30-L33 in lesion 2). A Contoured and fused transversal 
MRI slice on the level of lesion 2. B Systematic, transversal projection of the whole 
prostate. 
 
 
Figure 2. ROC-curves for the two density-groups (≤ 0.15 ng/ml/cm3/>0.15 
ng/ml/cm3) = line 1(AUC 0.674), PIRADS = line 2 (AUC 0.822) and the combination of 
density-groups and PIRADS = line 3 (AUC 0.846)  
 
 
 
  
Tables 
 
Table 1.  Clinical characteristics of the patients included in the study. Abbreviation: 
PSA = prostate-specific antigen. IQR = interquartile range. 
 
 Overall 
n=487 
 
Centre 1 
n=287 
 
Centre 2 
n=200 
 
 
Age (years): median / IQR 66 / 60-71 66 / 61-72 65 / 60-69 
PSA (ng/ml): median / IQR 9.0 / 6.7-13.4 9.7 / 7.1-13.9 7.9 / 6.0-11.8 
Prostate volume(ml):  
median / IQR 
56 / 40-80 
 
52 / 36-75 
 
66 / 44-84 
 
PSA- Density (ng/ml/ml): 
median / IQR 
0.15 / 0.10-
0.24 
0.17 / 0.12-
0.31 
0.13 / 0.09-
0.19 
Number of targeted cores 
Median / IQR 3 / 2-4 2 / 2-4 4 / 2-5 
Number of systematic 
cores median / IQR 24 / 24-26 24 / 24-25 24/ 23-26 
 
 
Table 2. Findings on multiparametric magnetic resonance imaging (MRI) in 487 men 
with suspicion of prostate cancer after previous negative biopsies.  
MRI findings All patients Centre 1 Centre 2 
 N % n % n % 
PIRADS 1-2 144 30% 91 32% 53 27% 
PIRADS 3-5 343 70% 196 68% 147 74% 
PIRADS 3 128 26% 76 26% 52 26% 
PIRADS 4 100 21% 58 20% 42 21% 
PIRADS 5 115 24% 62 22% 53 27% 
Total 487 100% 287 100% 200 100% 
  
Table 3. Biopsy results after a transperineal MRI/TRUS-fusion guided targeted and 
24-core systematic prostate biopsy. Abbreviation: GS = Gleason score.   
 Overall 
 
Centre 1 
 
Centre 2 
 
 n % n % n % 
            
All patients 487 100% 287 100%  200 100%  
Any cancer 249 51% 148 52% 101 51% 
GS 3+4=7 77 16% 44 15% 33 17% 
GS 4+3=7 44 9% 30 10% 14 7% 
GS 8-10 28 6% 13 5% 15 8% 
              
PIRADS 1-2:  144 100% 91 100% 53 100% 
Any cancer 40 28% 24 26% 16 30% 
GS 3+4=7 10 7% 5 5% 5 9% 
GS 4+3=7 0 0% 0 0% 0 0% 
GS 8-10  1 1% 0 0% 1 2% 
              
PIRADS 3-5:  343 100% 196 100% 147 100% 
Any cancer 209 61% 124 63% 85 58% 
GS 3+4=7  67 20% 39 20% 28 19% 
GS 4+3=7  44 13% 30 15% 14 10% 
GS 8-10  27 8% 13 7% 14 10% 
       
PIRADS 3:  128 100% 76 100% 52 100% 
Any cancer 56 44% 37 49% 19 37% 
GS 3+4=7 13 10% 8 11% 5 10% 
GS 4+3=7 9 7% 8 11% 1 2% 
GS 8-10 3 2% 1 1% 2 4% 
       
PIRADS 4:  100 100% 58 100% 42 100% 
Any cancer 58 58% 35 60% 23 55% 
GS 3+4=7 20 20% 10 17% 10 24% 
GS 4+3=7 6 6% 4 7% 2 5% 
GS 8-10 6 6% 4 7% 2 5% 
       
PIRADS 5:  115 100% 62 100% 53 100% 
Any cancer 95 83% 52 84% 43 81% 
GS 3+4=7 34 30% 21 34% 13 25% 
GS 4+3=7 29 25% 18 29% 11 21% 
 GS 8-10 18 16% 8 13% 10 19% 
 
Table 4. The negative (NPV) and positive (PPV) predictive values of multiparametric MRI using a transperineal MRI/TRUS-fusion 
guided targeted and 24-core systematic prostate biopsy as the reference test. Abbreviation: GS = Gleason score. 
 Overall 
n=487 
Centre 1 
n=287 
Centre 2 
n=200 
 n  95% CI n  95% CI n  95% CI 
PIRADS 1-2:                
NPV any 
cancer 104 0.72 
±0.07 
67 0.74 
±0.09 
37 0.70 
±0.12 
NPV GS 7-10 133 0.92 ±0.04 86 0.95 ±0.04 47 0.89 ±0.08 
NPV GS ≥ 4+3 
 143 0.99 
±0.02 
91 1.00 
±0.00 
52 0.98 
±0.04 
PIRADS 3-5:           
PPV any 
cancer 209 0.61 
±0.05 
124 0.63 
±0.07 
85 0.58 
±0.08 
PPV GS 7-10 138 0.40 ±0.05 82 0.42 ±0.07 56 0.38 ±0.08 
PPV GS ≥ 4+3 
 71 0.20 
±0.04 
43 0.22 
±0.06 
28 0.19 
±0.06 
PIRADS 3:           
PPV any 
cancer 56 0.44 
±0.09 
37 0.49 
±0.11 
19 0.37 
±0.13 
PPV GS 7-10 25 0.20 ±0.07 17 0.22 ±0.09 8 0.15 ±0.10 
PPV GS ≥ 4+3 
 12 0.09 
±0.05 
9 0.12 
±0.07 
3 0.06 
±0.06 
PIRADS 4:           
PPV any 
cancer 58 0.58 
±0.10 
35 0.60 
±0.13 
23 0.55 
±0.15 
PPV GS 7-10 32 0.32 ±0.09 18 0.31 ±0.12 14 0.33 ±0.14 
PPV GS ≥ 4+3 
 12 0.12 
±0.06 
8 0.14 
±0.09 
4 0.10 
±0.09 
PIRADS 5:           
PPV any 
cancer 95 0.83 
±0.07 
52 0.84 
±0.09 
43 0.81 
±0.11 
PPV GS 7-10 81 0.70 ±0.08 47 0.76 ±0.11 34 0.64 ±0.13 
PPV GS ≥ 4+3 47 0.41 ±0.09 26 0.42 ±0.12 21 0.40 ±0.13 
Table 5. The detection rates of transperineal MRI/TRUS-fusion guided targeted and 24-core systematic prostate biopsy depending 
on PSA density. Abbreviation: SB = systematic biopsy, TB = targeted biopsy. 
 Overal
l n=487 
Centr
e 1 n=287 
Centr
e 2 n=200 
 
n 
Detection 
rates % n 
Detection 
rates % n 
Detection 
rates % 
PIRADS 3-5       
PSA Density ≤ 
0.15  
164  76  88  
Overall GS7-10 
37 PPV 0.22 ± 
0.06 
14 PPV 0.18 ± 
0.09 
23 PPV 0.26 ± 
0.09 
TB GS7-10 24 65% 12 86% 12 52% 
SB GS7-10 32 87% 14 100% 18 78% 
       
PSA Density > 
0.15  
179  120  59  
Overall GS7-10 
101 PPV 0.56 ± 
0.07 
68 PPV 0.57 ± 
0.09 
33 PPV 0.56 ± 
0.13 
TB GS7-10 90 89% 62 92% 28 85% 
SB GS7-10 92 91% 64 94% 29 88% 
       
PIRADS 3       
PSA Density ≤ 
0.15  
80  38  42  
Overall GS7-10 9 
PPV 0.11 ± 
0.07 3 
PPV 0.08 ± 
0.09 6 
PPV 0.14 ± 
0.10 
TB GS7-10 2 22% 1 33% 1 17% 
SB GS7-10 9 100% 3 100% 6 100% 
       
 
 
 
 
PSA Density > 
0.15  
48  38  10  
Overall GS7-10 16 
PPV 0.33 ± 
0.13 14 
PPV 0.37 ± 
0.15 2 
PPV 0.20 ± 
0.25 
TB GS7-10 9 56% 9 64% 0 0% 
SB GS7-10 14 88% 13 93% 2 100% 
       
PIRADS 4-5       
PSA Density ≤ 
0.15 
84  38  46  
Overall GS7-10 28 
PPV 0.33 ± 
0.10 11 
PPV 0.29 ± 
0.14 17 
PPV 0.37 ± 
0.14 
TB GS7-10 22 79% 11 100% 11 65% 
SB GS7-10 23 82% 11 100% 12 71% 
       
PSA Density > 
0.15 
131  82  49  
Overall GS7-10 85 
PPV 0.65 ± 
0.08 54 
PPV 0.66 ± 
0.10 31 
PPV 0.63 ± 
0.14 
TB GS7-10 81 95% 53 98% 28 90% 
SB GS7-10 78 92% 51 94% 27 87% 
Table 6. The detection rates of transperineal MRI/TRUS-fusion guided targeted and 24-core systematic prostate biopsy for 
significant prostate cancer GS7-10. Abbreviation: SB = systematic biopsy, TB = targeted biopsy, n.c. = not calculated. 
 Overall n=487  Centre 1 n=287  Centre 2 n=200  
 
n 
Detection 
rates % 
p 
n 
Detection 
rates % 
p 
N 
Detection 
rates % 
p 
PIRADS 3:           
SB vs. TB 24 vs 11 96.0 vs 44.0 
0.001
9 16 vs 10 94.1 vs 58.8 
0.077
1 8 vs 1 
100.0 vs 
12.5 
0.0233 
Combination vs. 
TB 25 vs 11 
100.0 vs 
44.0 
0.000
5 17 vs 10 
100.0 vs 
58.8 
0.023
3 8 vs 1 
100.0 vs 
12.5 
0.0233 
Combination vs. 
SB 25 vs 24 
100.0 vs 
96.0 
1.000
0 17 vs 16 
100.0 vs 
94.1 
1.000
0 8 vs 8 
100.0vs 
100.0 
n.c. 
          
PIRADS 4:           
SB vs. TB 28 vs 29 87.5 vs 90.6 
1.000
0 18 vs 18 
100.0vs 
100.0 
n.c. 
10 vs 11 71.4 vs 78.6 
1.0000 
Combination vs. 
TB 32 vs 29 
100.0 vs 
90.6 
0.248
2 18 vs 18 
100.0vs 
100.0 
n.c. 
14 vs 11 
100.0 vs 
78.6 
0.2482 
Combination vs. 
SB 32 vs 28 
100.0 vs 
87.5 
0.133
6 18 vs 18 
100.0vs 
100.0 
n.c. 
14 vs 10 
100.0 vs 
71.4 
0.1336 
          
PIRADS 5:           
SB vs. TB 73 vs 74 90.1 vs 91.4 
1.000
0 44 vs 46 93.6 vs 97.9 
0.617
1 29 vs 28 85.3 vs 82.4 
1.0000 
Combination vs. 
TB 81 vs 74 
100.0 vs 
91.4 
0.023
3 47 vs 46 
100.0 vs 
97.9 
1.000
0 34 vs 28 
100.0 vs 
82.4 
0.0412 
Combination vs. 
SB 81 vs 73 
100.0 vs 
90.1 
0.013
3 47 vs 44 
100.0 vs 
93.6 
0.248
2 34 vs 29 
100.0 vs 
85.3 
0.0736 
 
 
 
 
 
Supplementary Table 1.  3.0 Tesla MRI protocols of the two different centers. Abbreviations: TR = Repetition Time, TE = Echo Time, 
ETL = Echo Train Length, FOV = Field of View, epi = Echo Planar Imaging, TSE = Turbo Spin Echo, SE = Spin Echo, DCE = Dynamic 
contrast enhancement. 
Parameter T1 TSE T2 TSE epi-2d DCE 
TR ms / TE ms 792/11 561/11 5120/142 4273/102 3100/52 3775/70 4.42/2.2 4.1/1.8 
Flip angle (*) 90 70 90 111 90 90 15 13 
ETL length / 
Epi-factor 72 4 12 16 96 1 x X 
Averages 2 2 4 1.5 5 6 x X 
b-value x x x x 
0, 50, 
100, 
150, 
200, 
250, 
800, 
1000 
150, 
750, 
1400 
x X 
Section 
thickness (mm) 5 8 3 3 3 3 1.5 3 
FOV (mm) 320 240 300 220 280 280 400 240 
Aquisation time 
(min) 03:51 03:43 04:14 06:59 05:04 02:58 05:18 05:57 
 
